For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $13.72 in the last session, up 1.33% from day before closing price of $13.54. In other words, the price has increased by $1.33 from its previous closing price. On the day, 0.58 million shares were traded. DAWN stock price reached its highest trading level at $13.78 during the session, while it also had its lowest trading level at $13.5.
Ratios:
We take a closer look at DAWN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 14.55 and its Current Ratio is at 14.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 18 ’24 when Bender Jeremy sold 10,554 shares for $13.21 per share. The transaction valued at 139,420 led to the insider holds 108,377 shares of the business.
Blackman Samuel C. sold 2,206 shares of DAWN for $29,142 on Nov 18 ’24. The HEAD OF R&D now owns 1,064,015 shares after completing the transaction at $13.21 per share. On Nov 18 ’24, another insider, Dubow Adam, who serves as the GENERAL COUNSEL of the company, sold 3,165 shares for $13.21 each. As a result, the insider received 41,810 and left with 32,162 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1383607168 and an Enterprise Value of 827843136. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.75 while its Price-to-Book (P/B) ratio in mrq is 2.49. Its current Enterprise Value per Revenue stands at 8.12 whereas that against EBITDA is -4.028.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $11.30. The 50-Day Moving Average of the stock is -4.39%, while the 200-Day Moving Average is calculated to be -5.92%.
Shares Statistics:
According to the various share statistics, DAWN traded on average about 1.06M shares per day over the past 3-months and 1013010 shares per day over the past 10 days. A total of 87.23M shares are outstanding, with a floating share count of 68.40M. Insiders hold about 32.17% of the company’s shares, while institutions hold 81.52% stake in the company. Shares short for DAWN as of 1731628800 were 18661330 with a Short Ratio of 17.55, compared to 1728950400 on 15976358. Therefore, it implies a Short% of Shares Outstanding of 18661330 and a Short% of Float of 22.35.
